Researchers at the University of Texas MD Anderson Cancer Center have found that castration-resistant prostate cancer responds well to a combination treatment comprised of immune checkpoint blockades and myeloid-derived suppressor cell (MDSC)-targeting th
Foresee Pharmaceuticals announced top-line result of FP-001 50mg phase 3 clinical trial, an open-label study in subjects with Advanced Prostate Carcinoma